Autoantibodies to tumor‐associated antigens: reporters from the immune system

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Immunological Reviews

• Publication date

  2008-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1600-065X.2008.00611.xPMID 18364012PMCID PMC2719766
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multiplexed protein array platforms for analysis of autoimmune diseases.

  2006cited by this paper
• Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays.

  2006cited by this paper
• Inefficient clearance of dying cells and autoreactivity.

  2006cited by this paper
• Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer.

  2006cited by this paper
• The sentinel within: exploiting the immune system for cancer biomarkers.

  2005cited by this paper
• T Cell–Dependent Antibody Responses against Aberrantly Expressed Cyclin B1 Protein in Patients with Cancer and Premalignant Disease

  2005cited by this paper
• Improved approach to identify cancer-associated autoantigens.

  2005cited by this paper
• An efficient proteomics-based approach for the screening of autoantibodies.

  2005cited by this paper
• Apoptosis and autoimmunity.

  2005cited by this paper
• Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor‐associated antigens

  2005cited by this paper
• Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display

  2004cited by this paper
• Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I

  2004cited by this paper
• Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide.

  2003cited by this paper
• Peptide-based treatment for autoimmune diseases: learning how to handle a double-edged sword.

  2003cited by this paper
• Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens.

  2003cited by this paper
• Relative paradigms between autoantibodies in lupus and autoantibodies in cancer

  2003cited by this paper
• Recursive partitioning as an approach to selection of immune markers for tumor diagnosis.

  2003cited by this paper
• Autoantigen microarrays for multiplex characterization of autoantibody responses

  2002cited by this paper
• Cancer vaccines: progress reveals new complexities.

  2002cited by this paper
• Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53.

  2002cited by this paper
• A Panel of Candidate Tumor Antigens in Colorectal Cancer Revealed by the Serological Selection of a Phage Displayed cDNA Expression Library1

  2002cited by this paper
• C‐MYC and IGF‐II mRNA‐binding protein (CRD‐BP/IMP‐1) in benign and malignant mesenchymal tumors

  2001cited by this paper
• Thyroid autoimmunity.

  2001cited by this paper
• Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis.

  2001cited by this paper
• Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies.

  2001cited by this paper
• Profiling the immune response in patients with breast cancer by phage‐displayed cDNA libraries

  2001cited by this paper
• Identification of tumor antigens in renal cell carcinoma by serological proteome analysis

  2001cited by this paper
• Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis.

  2001cited by this paper
• Autoimmune type 1 diabetes: resolved and unresolved issues.

  2001cited by this paper
• Identification of Cyclin B1 as a Shared Human Epithelial Tumor-Associated Antigen Recognized by T Cells

  2001cited by this paper
• Three Different Vaccines Based on the 140-Amino Acid MUC1 Peptide with Seven Tandemly Repeated Tumor-Specific Epitopes Elicit Distinct Immune Effector Mechanisms in Wild-Type Versus MUC1-Transgenic Mice with Different Potential for Tumor Rejection1

  2001cited by this paper
• Paraneoplastic neurologic disease antigens: RNA-binding proteins and signaling proteins in neuronal degeneration.

  2001cited by this paper
• Autoimmune diseases

  2000cited by this paper
• A microarray enzyme‐linked immunosorbent assay for autoimmune diagnostics

  2000cited by this paper
• p53 Antibodies in the sera of patients with various types of cancer: a review.

  2000cited by this paper
• Amplification in human breast cancer of a gene encoding a c-myc mRNA-binding protein.

  2000cited by this paper
• Why is Hu where? Shuttling of early-response-gene messenger RNA subsets.

  1999cited by this paper
• A Novel Cytoplasmic Protein with RNA-binding Motifs Is an Autoantigen in Human Hepatocellular Carcinoma

  1999cited by this paper
• Identifying potential conflicts of interest commercially sponsored research: establishing a policy for acceptable standards of disclosure.

  1999cited by this paper
• A Family of Insulin-Like Growth Factor II mRNA-Binding Proteins Represses Translation in Late Development

  1999cited by this paper
• Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders

  1999cited by this paper
• The c-myc coding region determinant-binding protein: a member of a family of KH domain RNA-binding proteins.

  1998cited by this paper
• Hepatitis B virus, the vaccine, and the control of primary cancer of the liver.

  1997influential reference
• Immune response to cyclin B1 in hepatocellular carcinoma

  1997cited by this paper
• Paraneoplastic syndromes.

  1997cited by this paper
• Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein

  1997cited by this paper
• Apoptosis and autoimmunity

  1997cited by this paper
• Serological analysis of human tumor antigens: molecular definition and implications.

  1997cited by this paper
• Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer.

  1996cited by this paper
• Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)- mediated T cell apoptosis

  1996cited by this paper
• Serum p53 antibodies as early markers of lung cancer

  1995cited by this paper
• Autoantibody to DNA topoisomerase II in primary liver cancer

  1995cited by this paper
• Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride.

  1995cited by this paper
• Insulin-like growth factors: the unrecognised oncogenes.

  1995cited by this paper
• Synthetic compound peptide simulating antigenicity of conformation-dependent autoepitope.

  1994cited by this paper
• Conserved structures and diversity of functions of RNA-binding proteins.

  1994cited by this paper
• Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface.

  1993cited by this paper
• Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma

  1993cited by this paper
• Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylase.

  1993cited by this paper
• Analysis of the anti-p53 antibody response in cancer patients.

  1993cited by this paper
• Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma.

  1993cited by this paper
• Autoantibodies in viral hepatitis-related hepatocellular carcinoma.

  1993cited by this paper
• Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.

  1992cited by this paper
• Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells.

  1991cited by this paper
• Peptide immunogen mimicry of a protein-specific structural epitope on human choriogonadotropin.

  1990cited by this paper
• Epitopes on protein antigens: misconceptions and realities.

  1990cited by this paper
• Insights into native epitopes of proliferating cell nuclear antigen using recombinant DNA protein products

  1990cited by this paper
• Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis.

  1990cited by this paper
• Injection of anticentromere antibodies in interphase disrupts events required for chromosome movement at mitosis

  1990cited by this paper
• Plant DNA topoisomerase I is recognized and inhibited by human Scl-70 sera autoantibodies.

  1990cited by this paper
• Regulation of proliferating cell nuclear antigen during the cell cycle.

  1989cited by this paper
• Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology.

  1989cited by this paper
• Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents.

  1989cited by this paper
• Interactions between autoimmunity and molecular and cell biology. Bridges between clinical and basic sciences.

  1989cited by this paper
• Myositis autoantibody reactivity and catalytic function of threonyl‐tRNA synthetase

  1988cited by this paper
• Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis.

  1988cited by this paper
• Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells.

  1988cited by this paper
• Autoantibody to RNA polymerase I in scleroderma sera.

  1987cited by this paper
• Autoreactive epitope defined as the anticodon region of alanine transfer RNA.

  1987cited by this paper
• The small nuclear ribonucleoprotein SS-B/La binds RNA with a conserved protease-resistant domain of 28 kilodaltons

  1987cited by this paper
• Epitopes on proliferating cell nuclear antigen recognized by human lupus autoantibody and murine monoclonal antibody.

  1987cited by this paper
• Functional identity of proliferating cell nuclear antigen and a DNA polymerase-δ auxiliary protein

  1987cited by this paper
• Autoantibody to the proliferating cell nuclear antigen neutralizes the activity of the auxiliary protein for DNA polymerase delta.

  1987cited by this paper
• Human autoantibody-reactive epitopes of SS-B/La are highly conserved in comparison with epitopes recognized by murine monoclonal antibodies

  1987cited by this paper
• High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients.

  1986cited by this paper
• Epitopes, structural domains, and asymmetry of amino acid residues in SS-B/La nuclear protein.

  1986cited by this paper
• An auxiliary protein for DNA polymerase-delta from fetal calf thymus.

  1986cited by this paper
• Hepatocellular carcinoma.

  1986influential reference
• The leader RNA of vesicular stomatitis virus is bound by a cellular protein reactive with anti-La lupus antibodies.

  1983cited by this paper
• Antinuclear, antinucleolar, and anticytoplasmic antibodies in patients with malignant melanoma.

  1983cited by this paper
• Precursor molecules of both human 5S ribosomal RNA and transfer RNAs are bound by a cellular protein reactive with anti-La lupus antibodies.

  1982cited by this paper
• Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer

  1982cited by this paper
• A nuclear antigen associated with cell proliferation and blast-transformation : its distribution in synchronized cells

  1982cited by this paper
• A nuclear antigen associated with cell proliferation and blast transformation

  1981cited by this paper
• A small nuclear ribonucleoprotein is required for splicing of adenoviral early RNA sequences.

  1981cited by this paper
• Autoantibody to a nuclear antigen in proliferating cells.

  1978cited by this paper
• AUTOANTIBODIES IN CANCER PATIENTS

  1977cited by this paper
• Antinuclear reactivity of sera in patients with leukemia and other neoplastic diseases.

  1975cited by this paper
• Profiles of antinuclear antibodies in systemic rheumatic diseases.

  1975cited by this paper
• [Paraneoplastic syndromes].

  1973cited by this paper

• Plasma anti-DLAT autoantibody as a novel diagnostic biomarker in breast cancer.

  2026cites this paper
• Bio-Inspired Smart Elastin-Like Polypeptides (ELPs) for Precision Drug Delivery: Molecular Strategies, Thermal Responsiveness, and Translational Advances.

  2026cites this paper
• Ophiuchus-Ab: A Versatile Generative Foundation Model for Advanced Antibody-Based Immunotherapy

  2026cites this paper
• Plasma IgG and IgM autoantibodies to COPT1 as potential biomarkers for detection of non-small cell lung cancer

  2025cites this paper
• Investigation of circulating natural autoantibodies against ANXA1 and MYC as potential biomarkers in hepatocellular carcinoma.

  2025cites this paper
• New Insights Into Diffuse Sclerosing Osteomyelitis: Is There a Role of ANA and Vitamin B6?

  2025cites this paper
• Tumor-Associated Autoantibodies Anti-p53 is Associated with Poor Prognosis in Patients with Lung Adenocarcinoma

  2025cites this paper
• The DCDC2/ENO1 axis promotes tumor progression and immune evasion in intrahepatic cholangiocarcinoma via activating FGL1-LAG3 checkpoint

  2025cites this paper
• Autoantibodies as Potential Liquid Biopsy Biomarker in Detection of Pancreatic Cancer: A Diagnostic Test Accuracy Review and Meta‐Analysis

  2025cites this paper
• Serum autoantibody profiles in cancer patients treated with immune checkpoint inhibitors: a cross-sectional study

  2025cites this paper
• A panel of four autoantibodies to tumour-associated antigens in patients with prostate cancer and its potential for multi-cancer detection

  2025cites this paper
• DeepNeoAG: Neoantigen epitope prediction from melanoma antigens using a synergistic deep learning model combining protein language models and multi-window scanning convolutional neural networks.

  2024cites this paper
• Anti-BIRC5 autoantibody serves as a valuable biomarker for diagnosing AFP-negative hepatocellular carcinoma

  2024cites this paper
• ESCCPred: a machine learning model for diagnostic prediction of early esophageal squamous cell carcinoma using autoantibody profiles

  2024cites this paper
• Autoantibodies in laryngeal cancer: detection and role as a biomarker.

  2024cites this paper
• Assessing the 9G Technology Blood Test for Predicting Lung Cancer in Patients with CT-Detected Lung Nodules: A Multicenter Clinical Trial

  2024cites this paper
• Combination of an autoantibody panel and alpha-fetoprotein for early detection of hepatitis B virus-associated hepatocellular carcinoma.

  2024cites this paper
• Exploiting Autophagy-Dependent Neoantigen Presentation in Tumor Microenvironment

  2023cites this paper
• Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs

  2023cites this paper
• ZPR1 is an immunodiagnostic biomarker and promotes tumor progression in esophageal squamous cell carcinoma

  2023influential citation
• Using Proteome Microarray and Gene Expression Omnibus Database to Screen Tumour-Associated Antigens to Construct the Optimal Diagnostic Model of Oesophageal Squamous Cell Carcinoma.

  2023cites this paper
• A Luminex Approach to Develop an Anti-Tumor-Associated Antigen Autoantibody Panel for the Detection of Prostate Cancer in Racially/Ethnically Diverse Populations

  2023cites this paper
• From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer

  2023cites this paper
• The Usefulness of the Ratio of Antigen–Autoantibody Immune Complexes to Their Free Antigens in the Diagnosis of Non-Small Cell Lung Cancer

  2023cites this paper
• A novel autoantibody signatures for enhanced clinical diagnosis of pancreatic ductal adenocarcinoma

  2023cites this paper
• Association of elevated autoantibody to high expression of GNAS in hepatocellular carcinoma

  2023cites this paper
• Human Proteome Microarray identifies autoantibodies to tumor‐associated antigens as serological biomarkers for the diagnosis of hepatocellular carcinoma

  2023cites this paper
• hccTAAb Atlas: An Integrated Knowledge Database for Tumor-Associated Autoantibodies in Hepatocellular Carcinoma.

  2023cites this paper
• The development of a tumor‐associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor‐based treatment in patients with advanced non‐small‐cell lung cancer

  2023cites this paper
• Site-specific protein biomarkers in gastric cancer: a comprehensive review of novel biomarkers and clinical applications

  2023cites this paper
• Liquid biopsy for early detection of lung cancer

  2023cites this paper
• Autoantibody to GNAS in Early Detection of Hepatocellular Carcinoma: A Large-Scale Sample Study Combined with Verification in Serial Sera from HCC Patients

  2022cites this paper
• Autoantibody against Tumor-Associated Antigens as Diagnostic Biomarkers in Hispanic Patients with Hepatocellular Carcinoma

  2022cites this paper
• Anti-CXCL8 Autoantibody: A Potential Diagnostic Biomarker for Esophageal Squamous Cell Carcinoma

  2022cites this paper
• Serum anti-SPP1 autoantibody as a potential novel biomarker in detection of esophageal squamous cell carcinoma

  2022cites this paper
• Identification of novel serological autoantibodies in Chinese prostate cancer patients using high-throughput protein arrays

  2022cites this paper
• Editorial: Tumor-associated antigens and their autoantibodies, from discovering to clinical utilization

  2022cites this paper
• ANA-HEp2 pattern evaluation in pancreatic cancer: What can the autoantibodies tell us?

  2022cites this paper
• Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab

  2022cites this paper
• Evaluating a Panel of Autoantibodies Against Tumor-Associated Antigens in Human Osteosarcoma

  2022cites this paper
• Serum Autoantibodies against LRDD, STC1, and FOXA1 as Biomarkers in the Detection of Ovarian Cancer

  2022cites this paper
• Anti-POSTN and Anti-TIMP1 Autoantibodies as Diagnostic Markers in Esophageal Squamous Cell Carcinoma

  2022cites this paper
• The combination of a seven-autoantibody panel with computed tomography scanning can enhance the diagnostic efficiency of non-small cell lung cancer

  2022cites this paper
• Matrix Effectors in the Pathogenesis of Keratinocyte-Derived Carcinomas

  2022cites this paper
• A novel immunodiagnosis panel for hepatocellular carcinoma based on bioinformatics and the autoantibody‐antigen system

  2021cites this paper
• Clinical and Molecular Features of Anti-CENP-B Autoantibodies

  2021cites this paper
• Tumor-associated autoantibodies in ESCC screening: Detecting prevalent early-stage malignancy or predicting future cancer risk?

  2021cites this paper
• Identification and validation of serum autoantibodies in children with B-cell acute lymphoblastic leukemia by serological proteome analysis

  2021cites this paper
• Integration of IgG and IgA Autoantibodies for Early Diagnosis of Hepatocellular Carcinoma.

  2021cites this paper
• Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma

  2021cites this paper
• Seven tumor‐associated autoantibodies as a serum biomarker for primary screening of early‐stage non‐small cell lung cancer

  2021cites this paper
• Immunomodulation: An immune regulatory mechanism in carcinoma therapeutics.

  2021cites this paper
• Development of a panel of autoantibody against NSG1 with CEA, CYFRA21-1, and SCC-Ag for the diagnosis of esophageal squamous cell carcinoma.

  2021cites this paper
• Seven Tumor-Associated Autoantibodies as a Eerum Biomarker for Primary Screening of Non-Small Cell Lung Cancer

  2021cites this paper
• Detection of Posttranslational Modification Autoantibodies Using Peptide Microarray.

  2021cites this paper
• Screening and Evaluating Novel Autoantibodies Based on Proteomic Chips in Diagnosis of Esophageal Squamous Cell Carcinoma

  2021cites this paper
• Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges

  2021cites this paper
• Presence of anti-TIF-1γ, anti-Ro52, anti-SSA/Ro60 and anti-Su/Ago2 antibodies in breast cancer: a cross-sectional study

  2021cites this paper
• Autoantibodies to tumor-associated antigens in lung cancer diagnosis.

  2021cites this paper
• Identification of novel autoantibody signatures and evaluation of a panel of autoantibodies in breast cancer

  2021cites this paper
• Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer

  2021cites this paper
• Autoimmunity Profiles as Prognostic Indicators in Patients with Colorectal Cancer versus Those with Cancer at Other Sites: A Prospective Study

  2021cites this paper
• Autoantibodies against p53, MMP-7, and Hsp70 as Potential Biomarkers for Detection of Nonmelanoma Skin Cancers

  2021cites this paper
• Identification of novel autoantibodies based on the protein chip encoded by cancer-driving genes in detection of esophageal squamous cell carcinoma

  2020cites this paper
• Using protein microarray to identify and evaluate autoantibodies to tumor‐associated antigens in ovarian cancer

  2020cites this paper
• Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers

  2020influential citation
• Serological Biomarkers for Early Detection of Hepatocellular Carcinoma: A Focus on Autoantibodies against Tumor-Associated Antigens Encoded by Cancer Driver Genes

  2020cites this paper
• The Combination of IgA and IgG autoantibodies against Transcriptional Intermediary Factor-1γ contributes to the early diagnosis of Lung Cancer

  2020cites this paper
• Twenty years of research on the DFS70/LEDGF autoantibody-autoantigen system: many lessons learned but still many questions

  2020cites this paper
• Discovery and Validation of Serum Autoantibodies Against Tumor-Associated Antigens as Biomarkers in Gastric Adenocarcinoma Based on the Focused Protein Arrays

  2020cites this paper
• Using Serological Proteome Analysis to Identify and Evaluate Anti-GRP78 Autoantibody as Biomarker in the Detection of Gastric Cancer

  2020cites this paper
• Anti‐C1GALT1 Autoantibody Is a Novel Prognostic Biomarker for Patients With Head and Neck Cancer

  2020cites this paper
• Screening of tumor-associated antigens based on Oncomine database and evaluation of diagnostic value of autoantibodies in lung cancer.

  2019cites this paper
• Quantification of CYFRA 21-1 and a CYFRA 21-1-anti-CYFRA 21-1 autoantibody immune complex for detection of early stage lung cancer.

  2019cites this paper
• Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness

  2019cites this paper
• Autoantibody against arrestin-1 as a potential biomarker of renal cell carcinoma.

  2019cites this paper
• High similarity of IgG antibody profiles in blood and saliva opens opportunities for saliva based serology

  2019cites this paper
• Specifics 1: Head and Neck Cancer and Esophageal Cancer

  2019cites this paper
• Serum anti-GAPDH autoantibody levels reflect the severity of cervical lesions: A potential serum biomarker for cervical cancer screening

  2019cites this paper
• Autoantibodies as diagnostic and prognostic cancer biomarker: Detection techniques and approaches.

  2019cites this paper
• Biomarkers in Cancer Therapy

  2019cites this paper
• Immunity against cancer cells may promote their proliferation and metastasis

  2019cites this paper
• Klinische Wertigkeit der Bestimmung von DFS70-Antikörpern für den Ausschluss von Kollagenosen

  2019cites this paper
• The Role Of p62/IMP2 In Hepatocellular Carcinoma Progression

  2019cites this paper
• Electrochemical biosensors for autoantibodies in autoimmune and cancer diseases

  2019cites this paper
• Using recursive partitioning approach to select tumor‐associated antigens in immunodiagnosis of gastric adenocarcinoma

  2019cites this paper
• Autoantigenomics: Holistic characterization of autoantigen repertoires for a better understanding of autoimmune diseases.

  2019cites this paper
• Establishment and validation of an immunodiagnostic model for prediction of breast cancer

  2019cites this paper
• MGMT autoantibodies as a potential prediction of recurrence and treatment response biomarker for glioma patients

  2019cites this paper
• Evaluation of a panel of tumor-associated antigens in breast cancer

  2019cites this paper
• Autoantibodies against tumor‐associated antigens combined with microRNAs in detecting esophageal squamous cell carcinoma

  2019cites this paper
• Using a panel of multiple tumor‐associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer

  2018influential citation
• Multiplexed Autoantibody Signature for Serological Detection of Canine Mammary Tumours

  2018cites this paper
• Semi-Automatic Analysis for Unidimensional Immunoblot Images to Discriminate Breast Cancer Cases Using Time Series Data Mining

  2018cites this paper
• Developments in Point-of-Care Diagnostic Technology for Cancer Detection

  2018cites this paper
• Gut immunoglobulin alpha anti-glycan binding profiles as a research tool for local disease detection

  2018cites this paper
• Peptide ligand-based ELISA reagents for antibody detection.

  2018cites this paper
• The Roles of Insulin-Like Growth Factor 2 mRNA-Binding Protein 2 in Cancer and Cancer Stem Cells

  2018cites this paper
• Using a panel of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of gastric cancer

  2018cites this paper
• Early detection of hepatocellular carcinoma using autoantibody profiles from a panel of tumor-associated antigens

  2018cites this paper